Andrew Aromando - Dec 11, 2023 Form 4 Insider Report for Ambrx Biopharma, Inc. (AMAM)

Role
Chief Operating Officer
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Andrew Aromando
Stock symbol
AMAM
Transactions as of
Dec 11, 2023
Transactions value $
$0
Form type
4
Date filed
12/11/2023, 05:19 PM
Previous filing
Jul 7, 2023
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMAM Common Stock Award $0 +100K +1079.56% $0.00 109K Dec 11, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the "Grant Date"). These RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan.
F2 The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter.